Showing 141-150 of 9754 results for "".
Take Your Reception Area to the Next Level
https://practicaldermatology.com/topics/practice-management/take-your-reception-area-to-the-next-level/23011/The next focus for your booming dermatology practice may be where you least expect. Here are simple steps to increase retail sales in your reception area.From Clinic to Capitol: Tips for Building Grassroots and Legislative Support For Anti-Tanning Policies in Your State
https://practicaldermatology.com/topics/skin-cancer-photoprotection/from-clinic-to-capitol-tips-for-building-grassroots-and-legislative-support-for-anti-tanning-policies-in-your-state/22943/It's no easy task to shepherd legislation through state assemblies, but dermatologists' clinical standing can have some influence.Is Bone Mineral Density Testing Indicated with Long-Term IM Triamcinolone Acetonide Therapy?
https://practicaldermatology.com/topics/general-topics/PD1208_05-php/22603/Prospective data are lacking, but early findings suggest little if any risk of density-loss among patients on long-term therapy.Eyeing a Treatment for Syringoma
https://practicaldermatology.com/series/scientifically-speaking/eyeing-a-treatment-for-syringoma/20112/Listen as Joel L. Cohen, MD describes early evidence for the use of nano pulse stimulation to treat syringoma, a notoriously challenging target.Panic-induced Digital Marketing: Avoid Short-sighted Shifts in Long-term Strategy
https://practicaldermatology.com/topics/practice-management/panic-induced-digital-marketing-avoid-short-sighted-shifts-in-long-term-strategy/26662/Panic-induced Digital Marketing: Avoid Short-sighted Shifts in Long-term StrategyPipeline Watch: Sizing Up a Promising Phase III IL-17 Biologic
https://practicaldermatology.com/topics/psoriasis/pipeline-watch-sizing-up-a-promising-phase-iii-il-17-biologic/21214/Pipeline Watch is a new Q&A feature appearing periodically in Practical Dermatology® that explores the potential of therapeutic agents currently under investigation. In each edition, we will speak with investigators from manufacturing companies to gain insights about the development and investigDermWireTV: International Launch of AviClear; Biological Effects of Air Pollution on Human Skin; New AAD Guidelines for Acne Care
https://practicaldermatology.com/series/dermwire-tv/dermwiretv-international-launch-of-aviclear-biological-effects-of-air-pollution-on-human-skin-new-aad-guidelines-for-acne-care/20261/In this episode of DermWireTV, we report on the international launch of the first energy-based device FDA-cleared for the long-term treatment of mild, moderate, and severe acne. An expert discusses a recent study that examines the biological effects of air pollution on human skin equivalents. For thEnsuring Excellent Care Across LGBTQ and Sexual Minority Patients
https://practicaldermatology.com/topics/practice-management/ensuring-excellent-care-across-lgbtq-and-sexual-minority-patients/20077/The session on LGBTQ and sexual gender minority health covered a range of topics including both clinical care as well as terminology, structures, and framework. Klint Peebles, MD talks about the importance of providing excellent dermatologic care as patients face disparities and challenges in accessDermWireTV: LEO Science & Tech Hub, Allergan/SkinBetter DREAM Initiative, San Diego Dermatology Symposium
https://practicaldermatology.com/topics/skin-cancer-photoprotection/dermwiretv-leo-pharma-science-tech-hub-allerganskinbetter-dream-initiative-san-diego-dermatology-symposium/19856/Innovation Endeavors and the LEO Science & Tech Hub kick off a Deep Life Challenge program. Allergan Aesthetics, an AbbVie company, and Skinbetter Science launch a new long-term, educational initiative: The DREAM (Driving Racial Equity in Aesthetic Medicine) Initiative. The San Diego DermatologyDupixent for Adolescents priority review, Restylane Lyft via cannulas, Hyperhidrosis Awareness
https://practicaldermatology.com/series/dermwire-tv/dermwire-tv-dupixent-for-adolescents-priority-review-restylane-lyft-via-cannulas-hyperhidrosis-awareness/18215/FDA grants priority review for Sanofi's and Regeneron's sBLA for Dupixent (dupilumab) for adolescents. Galderma's Restylane Lyft is approved for use with a small, blunt-tip cannula for cheek augmentation and the correction of age-related midface contour deficiencies in patients over the age of 21. T